Endocrinology Panel Examines Interplay Between Diabetes and Cardiovascular Disease in New Report
...t (sitagliptin; Merck), Byetta (exenatide; Lilly/Amylin), exenatide LAR (Lilly/Amylin/Alkermes), Symlin (Amylin), pramlintide + leptin (Amylin/Amgen), galvus (vildagliptin; Novartis), alogliptin (Takeda), saxagliptin (BMS/AZ), Redona (denagliptin; GSK), liraglutide (Novo Nordisk), Boc5 (UC Riverside / Chine...Galvus Soon To Be Seen On European Shelves
...Medicines Agency. Now open to the European market, galvus has nevertheless still no access to its American ...er Novartis said it would not be ready to resubmit galvus to U.S. regulators until mid-2009, due to a reques...n delayed by worries over skin toxicity. Both galvus and Januvia are so-called DPP-4 inhibitors, which ...Galvus (vildagliptin) - DPP-IV Inhibitor / Oral Antidiabetic Agent ...
News and project information on the Vildagliptin oral antidiabetic agent from Novartis. ... Galvus (vildagliptin), in advanced-stage development as a treatment ...New safety issues to delay Novartis's Galvus | Markets | Markets News ...
By Sam Cage ZURICH (Reuters) - Novartis AG has found new liver safety problems with high doses of its diabetes medicine Galvus, delaying the key drug's path to ...Galvus®, a new treatment for patients with type 2 diabetes, receives ...
Basel, February 1, 2008 - European health authorities have approved Galvus® (vildagliptin) as a new oral treatment for type 2 diabetes patients, paving the way for ...Galvus®, a new oral treatment for type 2 diabetes, receives positive ...
Basel, December 17, 2007 - European health authorities have supported changes proposed by Novartis to prescribing information for Galvus® (vildagliptin), opening ...